Massimo Bani

2.3k total citations
48 papers, 1.7k citations indexed

About

Massimo Bani is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Cognitive Neuroscience. According to data from OpenAlex, Massimo Bani has authored 48 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Cellular and Molecular Neuroscience, 12 papers in Molecular Biology and 12 papers in Cognitive Neuroscience. Recurrent topics in Massimo Bani's work include Neuropeptides and Animal Physiology (10 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (10 papers) and Receptor Mechanisms and Signaling (8 papers). Massimo Bani is often cited by papers focused on Neuropeptides and Animal Physiology (10 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (10 papers) and Receptor Mechanisms and Signaling (8 papers). Massimo Bani collaborates with scholars based in Italy, United Kingdom and United States. Massimo Bani's co-authors include Renan Campos Chisté, Francesco Makovec, I Setnikar, Laura Revel, Emilio Merlo Pich, Tomas Furmark, Fredrik Åhs, Emilio Merlo‐Pich, Lieuwe Appel and John D. Beaver and has published in prestigious journals such as Journal of Neuroscience, NeuroImage and Biological Psychiatry.

In The Last Decade

Massimo Bani

46 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Massimo Bani Italy 26 797 431 402 261 224 48 1.7k
Stephanie Grant United States 17 980 1.2× 548 1.3× 764 1.9× 197 0.8× 88 0.4× 40 2.2k
Jaana Kajander Finland 24 636 0.8× 221 0.5× 455 1.1× 153 0.6× 137 0.6× 33 1.6k
David Nutt United Kingdom 29 1.3k 1.7× 758 1.8× 480 1.2× 387 1.5× 132 0.6× 72 2.5k
Gábor Oroszi United States 21 1.1k 1.4× 651 1.5× 222 0.6× 142 0.5× 98 0.4× 40 2.5k
Richard M. Mangano United States 21 813 1.0× 521 1.2× 576 1.4× 786 3.0× 178 0.8× 35 2.4k
Hugo A. Jørgensen Norway 25 492 0.6× 263 0.6× 385 1.0× 105 0.4× 248 1.1× 83 1.9k
Joseph P. Schacht United States 21 1.0k 1.3× 175 0.4× 712 1.8× 200 0.8× 138 0.6× 45 1.9k
Abhishekh H. Ashok United Kingdom 19 614 0.8× 311 0.7× 368 0.9× 124 0.5× 103 0.5× 42 1.8k
Yoshio Yamanouchi Japan 32 728 0.9× 872 2.0× 232 0.6× 154 0.6× 51 0.2× 122 2.8k

Countries citing papers authored by Massimo Bani

Since Specialization
Citations

This map shows the geographic impact of Massimo Bani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Massimo Bani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Massimo Bani more than expected).

Fields of papers citing papers by Massimo Bani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Massimo Bani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Massimo Bani. The network helps show where Massimo Bani may publish in the future.

Co-authorship network of co-authors of Massimo Bani

This figure shows the co-authorship network connecting the top 25 collaborators of Massimo Bani. A scholar is included among the top collaborators of Massimo Bani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Massimo Bani. Massimo Bani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Otoul, Christian, M. Macpherson, Mark Watling, et al.. (2023). Clinical Bridging Studies and Modeling Approach for Implementation of a Patient Centric Sampling Technique in Padsevonil Clinical Development. The AAPS Journal. 26(1). 1–1. 4 indexed citations
2.
Price, D. L., Asma Khan, Rachel Angers, et al.. (2023). In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease. npj Parkinson s Disease. 9(1). 114–114. 16 indexed citations
3.
Mercier, Joël, Massimo Bani, Anny‐Odile Colson, et al.. (2023). Evaluation and Application of a PET Tracer in Preclinical and Phase 1 Studies to Determine the Brain Biodistribution of Minzasolmin (UCB0599). Molecular Imaging and Biology. 26(2). 310–321. 3 indexed citations
4.
Regnault, Antoine, Babak Boroojerdi, Juliette Meunier, et al.. (2019). Does the MDS-UPDRS provide the precision to assess progression in early Parkinson’s disease? Learnings from the Parkinson’s progression marker initiative cohort. Journal of Neurology. 266(8). 1927–1936. 119 indexed citations
5.
Conrado, Daniela J., Timothy Nicholas, Kuenhi Tsai, et al.. (2017). Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis. Clinical and Translational Science. 11(1). 63–70. 35 indexed citations
6.
Bergman, Olle, Fredrik Åhs, Tomas Furmark, et al.. (2014). Association between amygdala reactivity and a dopamine transporter gene polymorphism. Translational Psychiatry. 4(8). e420–e420. 20 indexed citations
7.
Erritzøe, David, Andri C. Tziortzi, David Bargiela, et al.. (2014). In Vivo Imaging of Cerebral Dopamine D3 Receptors in Alcoholism. Neuropsychopharmacology. 39(7). 1703–1712. 49 indexed citations
8.
Faria, Vanda, Fredrik Åhs, Lieuwe Appel, et al.. (2014). Amygdala-frontal couplings characterizing SSRI and placebo response in social anxiety disorder. The International Journal of Neuropsychopharmacology. 17(8). 1149–1157. 25 indexed citations
9.
Bani, Massimo, Anne C. Andorn, & Christian Heidbreder. (2013). Pharmacologically, are smokers the same as non-smokers?. Current Opinion in Pharmacology. 14. 42–49. 3 indexed citations
10.
Giménez, Mònica, Héctor Ortiz, Carles Soriano‐Mas, et al.. (2013). Functional effects of chronic paroxetine versus placebo on the fear, stress and anxiety brain circuit in Social Anxiety Disorder: Initial validation of an imaging protocol for drug discovery. European Neuropsychopharmacology. 24(1). 105–116. 21 indexed citations
11.
Dodds, Chris, Barry V. O’Neill, John D. Beaver, et al.. (2012). Effect of the dopamine D3 receptor antagonist GSK598809 on brain responses to rewarding food images in overweight and obese binge eaters. Appetite. 59(1). 27–33. 29 indexed citations
12.
Mugnaini, Manolo, Laura Iavarone, Cristiana Griffante, et al.. (2012). Occupancy of Brain Dopamine D3 Receptors and Drug Craving: A Translational Approach. Neuropsychopharmacology. 38(2). 302–312. 68 indexed citations
13.
Faria, Vanda, Lieuwe Appel, Fredrik Åhs, et al.. (2012). Amygdala Subregions Tied to SSRI and Placebo Response in Patients with Social Anxiety Disorder. Neuropsychopharmacology. 37(10). 2222–2232. 54 indexed citations
14.
Searle, Graham E., John D. Beaver, Andri C. Tziortzi, et al.. (2012). Mathematical modelling of [11C]-(+)-PHNO human competition studies. NeuroImage. 68. 119–132. 33 indexed citations
15.
Nathan, Pradeep J., Barry V. O’Neill, Karin Mogg, et al.. (2011). The effects of the dopamine D3 receptor antagonist GSK598809 on attentional bias to palatable food cues in overweight and obese subjects. The International Journal of Neuropsychopharmacology. 15(2). 149–161. 46 indexed citations
16.
Mathew, Sanjay J., Meena Vythilingam, James W. Murrough, et al.. (2010). A selective neurokinin-1 receptor antagonist in chronic PTSD: A randomized, double-blind, placebo-controlled, proof-of-concept trial. European Neuropsychopharmacology. 21(3). 221–229. 40 indexed citations
17.
Goméni, Roberto, et al.. (2001). Computer-assisted drug development (CADD): an emerging technology for designing first-time-in-man and proof-of-concept studies from preclinical experiments. European Journal of Pharmaceutical Sciences. 13(3). 261–270. 25 indexed citations
18.
19.
Benedetti, M. Strolin & Massimo Bani. (1999). METABOLISM-BASED DRUG INTERACTIONS INVOLVING ORAL AZOLE ANTIFUNGALS IN HUMANS*. Drug Metabolism Reviews. 31(3). 665–717. 20 indexed citations
20.
Breda, Massimo, M. Strolin Benedetti, Massimo Bani, et al.. (1999). EFFECT OF RIFABUTIN ON ETHAMBUTOL PHARMACOKINETICS IN HEALTHY VOLUNTEERS. Pharmacological Research. 40(4). 351–356. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stephanie Grant Breakdown of academic impact, for papers by Jaana Kajander Breakdown of academic impact, for papers by David Nutt Breakdown of academic impact, for papers by Gábor Oroszi Breakdown of academic impact, for papers by Richard M. Mangano Breakdown of academic impact, for papers by Hugo A. Jørgensen Breakdown of academic impact, for papers by Joseph P. Schacht Breakdown of academic impact, for papers by Abhishekh H. Ashok Breakdown of academic impact, for papers by Yoshio Yamanouchi
Rankless by CCL
2026